In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

More than 8 million Americans live with psoriasis every day. Living with the chronic disease can be a long journey for many ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Biologics ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Targeted and biologic therapies remained in various stages of development. The most recent AAD/National Psoriasis Foundation (NPF) clinical guidelines, published from 2019 to 2021, consist of six ...

In the United States, people with skin of color wait longer for a psoriasis diagnosis, are more likely to have severe symptoms, and are less likely to use biologic therapy than white Americans.